Key result
Transcatheter mitral valve repair improves quality-adjusted life-years vs GDMT at ~$55,600 per QALY gained.
Why the study?
Whether transcatheter mitral valve repair is cost-effective compared with guideline-directed medical therapy in patients with heart failure and 3 to 4+ secondary mitral regurgitation was unknown.
Is transcatheter mitral valve repair cost-effective compared with medical therapy alone in patients with heart failure and severe secondary mitral regurgitation?
RCT
Is transcatheter mitral valve repair cost-effective compared with medical therapy alone in patients with heart failure and severe secondary mitral regurgitation?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“For symptomatic heart-failure patients with 3 to 4+ symptomatic mitral regurgitation, [transcatheter mitral valve repair (TMVr)] increases quality-adjusted life-expectancy compared with GDMT at an incremental cost per QALY gained consistent with intermediate-to-high economic value based on currently accepted US thresholds. Future studies are needed to examine the durability of TMVr benefit in this population and to evaluate the cost-effectiveness of TMVr compared with other available and emerging mitral valve therapies.”
“The availability of updated survival analyses from the COAPT pivotal trial suggests previous estimates based on 2-year trial findings were over optimistic for the intervention.”
“Clearly, the Clip did better than guideline-directed medical therapy.”
Transcatheter mitral valve repair provides acceptable economic value according to current US thresholds for patients with heart failure and severe secondary mitral regurgitation.
BACKGROUND: The COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted in reduced mortality and heart failure hospitalizations and improved quality of life compared with maximally tolerated guideline-directed medical therapy (GDMT) in patients with heart failure and 3 to 4+ secondary mitral regurgitation. Whether TMVr is cost-effective compared with GDMT in this population is unknown. METHODS: We used data from the COAPT trial to perform a formal patient-level economic analysis of TMVr+GDMT versus GDMT alone for patients with heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare system. Costs for the index TMVr hospitalization were assessed using a combination of resource-based accounting and hospital billing data (when available). Follow-up medical care costs were estimated on the basis of medical resource use collected during the COAPT trial. Health utilities were estimated for all patients at baseline and 1, 6, 12, and 24 months with the Short Form Six-Dimension Health Survey. When in-trial survival, health utilities, and costs were modeled over a lifetime horizon, TMVr was projected to increase life expectancy by 1.13 years and quality-adjusted life-years by 0.82 years at a cost of $45 648, yielding a lifetime incremental cost-effectiveness ratio of $40 361 per life-year gained and $55 600 per quality-adjusted life-year gained. CONCLUSIONS: For symptomatic patients with heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and quality-adjusted life expectancy compared with GDMT at an incremental cost per quality-adjusted life-year gained that represents acceptable economic value according to current US thresholds. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01626079.
No takes yet. Share an insight, caveat, or question.
Baron et al. (2019) conducted an RCT in Heart failure and secondary mitral regurgitation. Transcatheter mitral valve repair (TMVr) + GDMT vs. Guideline-directed medical therapy (GDMT) alone was evaluated on Lifetime incremental cost-effectiveness ratio ($55 600 per QALY gained, p=<0.001). Transcatheter mitral valve repair increased quality-adjusted life-years by 0.82 years compared with GDMT, yielding an incremental cost-effectiveness ratio of $55,600 per QALY gained.
Synapse has enriched 10 related papers. Consider them for comparative context: